Since many of the biomarkers in the bladder cancer-associated diagnostic panel are known immunomodulators, we assessed the bladder tumors for the presence of CD3+ cells (pan-T cell) and CD68+ cells (macrophage) as a snapshot of the tumor immune landscape. The gene discussed is CD68; the disease is urinary bladder cancer.